Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease

doi:10.4292/wjgpt.v17.i1.112788

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-8) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-8)

Sum=27

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=0

Mar 5, 2026 (publication date) through Feb 11, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Pharmacol Ther. Mar 5, 2026; 17(1): 112788
Published online Mar 5, 2026. doi: 10.4292/wjgpt.v17.i1.112788

Open in New Tab Full Size Figure Download Figure

Figure 1 Mechanism of action of various Janus kinase inhibitors and their downstream effects. IL: Interleukin; IFN: Interferon; JAK: Janus kinase; TYK2: Tyrosine kinase 2; STAT: Signal transducer and activator of transcription.

Open in New Tab Full Size Figure Download Figure

Figure 2 Checklist before initiation and monitoring after initiation of Janus kinase inhibitors in inflammatory bowel disease. JAK: Janus kinase; IBD: Inflammatory bowel disease; IGRA: Interferon gamma release assay; HRCT: High-resolution computed tomography; HBsAg: Hepatitis B surface antigen; anti-HBc: Hepatitis B core antibody; anti-HBs: Hepatitis B surface antibody; CBC: Complete blood count; LFT: Liver function test.

Citation: Malakar S, Giri S, Jena A, Nath P. Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2026; 17(1): 112788
URL: https://www.wjgnet.com/2150-5349/full/v17/i1/112788.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v17.i1.112788